Loading company details...
Beta
Latest Form 4 (Sep 30, 2024): Kevin M. Lalande (Director): Grant/Award of 1,000 shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2024 | Kevin M. Lalande | Grant/Award | 1,000 | n/a |
| Sep 30, 2024 | Gabriela Gruia | Grant/Award | 1,000 | n/a |
| Sep 30, 2024 | Harold E. Selick | Grant/Award | 1,000 | n/a |
| Sep 30, 2024 | Dave Hoffmann | Grant/Award | 1,000 | n/a |
| Sep 30, 2024 | Corazon (Corsee) D. Sanders | Grant/Award | 1,000 | n/a |
| Apr 4, 2024 | Target N. Biotech V | Purchase | 250,000 | $587.5K |
| Apr 4, 2024 | Kevin M. Lalande | Grant/Award | 175,000 | $411.3K |
| Jan 25, 2024 | Maurizio Voi, Chief Medical Officer | Grant/Award | 10,000 | n/a |
| Jan 25, 2024 | Jason S. Kim, Chief Financial Officer | Grant/Award | 10,000 | n/a |
| Jan 25, 2024 | Eric E. Poma, Chief Executive Officer and Chief Scientific Officer | Grant/Award | 23,333 | n/a |